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of tuberculosis treatment in Central Asia:







Background: Illness-related costs incurred by patients constitute a severe economic burden for households
especially in low-income countries. High household costs of illness lead to impoverishment; they impair
affordability and equitable access to health care and consequently hamper tuberculosis (TB) control. So far, no
study has investigated patient costs of TB in the former Soviet Union.
Methods: All adult new pulmonary TB cases enrolled into the DOTS program in 12 study districts during the study
period were enrolled. Medical and non-medical expenditure as well as loss of income were quantified in two
interviews covering separate time periods. Costs of different items were summed up to calculate total costs. For
missing values, multiple imputation was applied.
Results: A cohort of 204 patients under DOTS, 114 men and 90 women, participated in the questionnaire survey.
Total illness costs of a TB episode averaged $1053 (c. $4900 purchasing power parity, PPP), of which $292, $338
and $422 were encountered before the start of treatment, during intensive phase and in continuation phase,
respectively. Costs per month were highest before the start of treatment ($145) and during intensive phase ($153)
and lower during continuation phase ($95). These differences were highly significant (paired t-test, p < 0.0005 for
both comparisons).
Conclusions: The illness-related costs of an episode of TB exceed the per capita GDP of $1600 PPP about two-
and-a-half times. Hence, these costs are catastrophic for concerned households and suggest a high risk for
impoverishment. Costs are not equally spread over time, but peak in early stages of treatment, exacerbating the
problem of affordability. Mitigation strategies are needed in order to control TB in Tajikistan and may include social
support to the patients as well as changes in the management of TB cases. These mitigation strategies should be
timed early in treatment when the cost burden is highest.
Background
Illness often leads to substantial economic burden for
the patients and their households, especially in resource-
poor settings and in the absence of social support
mechanisms [1,2]. Economic costs of illness at the
household level-below referred to as household costs-
have strong implications for issues of poverty and equi-
table access to health care. A review found that ill-
health, especially long-lasting disease including tubercu-
losis (TB), puts households at high risk of
impoverishment [1]. Poor households are deterred from
the use of health care due to household costs, prevent-
ing the health services from reaching those most in
need [3]. In the case of TB, where the main control and
prevention measure consists of treating active disease
[4], it must therefore be expected, that high household
costs have a negative impact on TB control.
There have been many studies on cost-effectiveness of
different TB control strategies, mainly investigating the
costs to the health system. Important findings of these
studies include the feasibility and cost-effectiveness of
short-course TB chemotherapy on a predominantly
ambulatory basis [5-10]. Far fewer studies measured the
costs to households [11-13]. One of the first studies to
* Correspondence: raffael.aye@unibas.ch
1Swiss Tropical Institute, Swiss Centre for International Health, Socinstr. 57,
4002 Basel, Switzerland
Ayé et al. BMC Public Health 2010, 10:18
http://www.biomedcentral.com/1471-2458/10/18
© 2010 Ayé et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.comprehensively measure household costs found that
the costs of an episode of TB in Thailand amounted to
20% of annual household income in the poorest third of
patients and thus were devastating [12]. Other studies
also found that household costs of an episode of TB
were considerable-ranging from $186 to $1457 in Tan-
zania depending on treatment duration and around
$920 in China [13,14]. A number of studies investigated
reasons for delay to treatment and consequently mea-
sured only the costs up to diagnosis and registration
with the TB control program [15-17]. Also when study-
ing the economic impact on households, this strategy
may be tempting, based on the rationale that TB treat-
ment should be free of charge afterwards. However,
those studies that measured costs after enrolment in TB
control programs invariably found considerable costs
during treatment [1,12-14]. In his review, Russell [1]
found that “health expenditures tended to be lumpy,
coming in peaks that intensified cost burdens over a few
days or weeks”.H o w e v e r ,t oo u rk n o w l e d g es of a rn o
study looked at the distribution of household costs of
TB over time other than differentiating before diagnosis
and after diagnosis.
Tajikistan is the poorest republic of the former Soviet
Union with a per capita gross domestic product (GDP)
of $1600 purchasing power parity (PPP, 2007 estimate)
[18]. The country’s infrastructure was severely damaged
during the civil war from 1992 to 1998. Many villages
and even whole districts are cut off in winter from elec-
tricity supply and transportation axes in this mountai-
nous country. The economy of Tajikistan is highly
informal and it has been observed that the grey econ-
omy is more important in several respects than the offi-
cial economy [19]. Corruption is widespread and
Transparency International ranks Tajikistan number 151
out of 180 countries in their perceived corruption index
[20]. Temporary labour migration to Russia is very com-
mon, especially among young men. The health system is
still very specialised, hierarchical and at least nominally
comprehensive as in the Soviet Union [21]. Profound
health sector and health financing reform is ongoing.
Patients have to pay predefined fees for specific services
above the primary care level, with different fee rates
depending on referral or non-referral of the patient
from primary care level. Informal payments are wide-
spread also in the health system and out-of-pocket pay-
ments may constitute as much as 80% of total health
funding [22]. In a recent survey in two districts piloting
a new primary care model, almost half of the patients
who had visited a family doctor reported that they had
made an informal payment [23]. Involvement of the pri-
vate sector in health care is very limited and virtually
nonexistent outside the capital. The WHO estimate of
TB incidence was 204 cases per 100,000 per year in
2006 [24], while the national TB control program esti-
mated incidence between 160 and 180 cases per 100,000
per year. The country began DOTS implementation in
2002 and DOTS coverage reached 100% by the end of
2007. A study in ten districts of Tajikistan showed that
the hospitalisation rate of TB patients was high (58%)
and that a positive sputum smear result was the main
predictor of hospitalisation [25]. For patients who are
not hospitalised, the program foresees facility-based
observation of treatment.
In most settings in the former Soviet Union anti-TB
drugs are provided for free, but patients have to pay for
other services including additional medicines, x-rays and
laboratory services and potentially face major financial
barriers [26]. In urban Ukraine, total illness-related costs
of TB varied from $57 to $450 depending on the TB
control strategy and on the locality [27]. These costs
were often outweighed by the social benefits provided to
TB patients. Overall, very little is known about illness-
related costs of TB in the former Soviet Union. This
study aimed at quantifying household costs of an epi-
sode of TB in Tajikistan, with special attention to the
time period, when costs were incurred.
Methods
Study population
Only districts with an established DOTS program were
considered for inclusion in the study. Two regions were
excluded because they were accessible only by air at the
time of the study, Badakhshan and Sughd. In close colla-
boration with the Republican Centre for TB control of
Tajikistan, 12 districts were purposefully selected to
represent different urban, rural, lowland and mountai-
nous settings. All pulmonary TB patients at least 15
years of age who were registered for the first time (i.e.
“new” patients according to WHO definition) in the 12
study districts in the period from 1
st December 2006
until 31
st M a r c h2 0 0 7w e r ee l i g i b l ef o rs t u d yp a r t i c i p a -
tion. Patients who had defaulted from treatment before
the first interview were excluded. Patients who defaulted
d u r i n go ra tt h ee n do ft h ei n t e n s i v ep h a s ew e r e
excluded from the second interview, as they could not
possibly give information on the continuation phase.
Questionnaire and Interviews
Patients were visited in hospital or at home during the
intensive phase of treatment, written informed consent
was obtained and the first interview conducted. Three
to four months later, the same patients were visited for
a follow-up interview. The first interview covered the
period before diagnosis, starting from the time point,
when the patients experienced the first symptoms, and
the intensive phase. The follow-up interview covered the
continuation phase. The costs from the day of interview
until the end of the respective phase were extrapolated,
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tion phase. The questionnaires were adapted from a
questionnaire used for the quantification of costs of
HIV/AIDS [28]. They were piloted and finalised prior to
the start of data collection. They are available from the
authors upon request. Completing an interview took
about one hour on average. The questionnaires included
detailed questions about health care seeking, about the
costs incurred by patients and their households and
about household assets. Household costs included medi-
cal expenditure (for drugs, medical fees and laboratory
tests), non-medical expenditure (for transport, special
food items, modification of housing, traditional healers,
self-treatment and any other reported expenditures),
a n dl o s so fi n c o m ed u et ot h ei n a b i l i t yt ow o r k .T o
quantify loss of income, patients were asked about the
actual reduction of income that they themselves and
caretakers had experienced due to absence from their
usual income-generating activities for a day. This daily
income reduction was then multiplied with the number
of days away from work. If patients did not know the
income reduction for one day, but could give an esti-
mate for the total income reduction until the day of
interview, the total estimate was registered and divided
by the number of days away from work during data
entry. Where income was in-kind, like sometimes in
agriculture, the monetary value was estimated. Informa-
tion on treatment outcome could not be obtained, as
treatment was not completed at the time of the
interview.
Interviewers were trained for two weeks before con-
ducting real interviews and supervised at least twice per
month through interviews conducted together with the
main researcher. Specific emphasis was given to support
the patients in their recall work, including the use of a
calendar of locally important events, to motivate the
patient to provide accurate information on costs and to
ask back if reported costs were unexpectedly high or
low for local context. Data were entered by the main
researcher in FileMaker (version 8.0v1, FileMaker Inc,
USA, 1984-2005).
Data Analysis
A l la n a l y s e sw e r ec o n d u c t e di nS t a t aI C / 1 0 . 1f o rM a c i n -
tosh (Stata Corporation, USA, 1985-2008). Individual
cost items were summed up to the categories of medical
costs, non-medical costs, and lost income-for each of
the three phases of treatment separately (before start of
treatment, intensive phase, and continuation phase). For
conversion of Tajik Somonis to international US$ PPP,
we used data provided by the World Bank [29].
In order to avoid the problems associated with com-
plete case analysis and as recommended by Manca and
Palmer [30] for similar problems, we used multiple
imputation to deal with missing observations,
implemented in the function “ice” in Stata [31,32]. The
algorithm in “ice” assumes normally distributed vari-
ables; this was assured through transformation to nor-
mal scores. The statistical comparisons of costs during
the different phases were done with a paired t-test
because we were mainly interested in the pair wise com-
parisons (n = 204 for all comparisons). To correct for
the fact that we conducted three t-tests, we decreased
our significance level to 1.67%. We plotted the residuals
and checked visually whether the distributions were nor-
mal. In order to normalise the distribution of residuals,
we used log-transformation.
We conducted a principal component analysis on 18
variables to construct a wealth index following the
methodology described by Filmer and Pritchett [33].
The 18 variables included 15 household assets and three
housing characteristics. To improve validity of the
wealth measure, we used continuous variables, where
this was possible, and we did not recode any categorical
v a r i a b l e sa sd u m m i e s[ 3 4 ] .S u b j e c t sw e r ea l l o c a t e dt o
five quintiles by their wealth index. To investigate the
internal consistency of our measure of socio-economic
status (SES), we plotted the mean of each asset variable
against SES quintile and found that the asset variables
were highly consistent with expectations.
The study has received ethical approval from the Min-
istry of Health of the Republic of Tajikistan.
Results
In the 12 study districts, 282 eligible patients were regis-
tered for treatment during the recruitment time.
Seventy-eight (28%) of them were not interviewed,
because they did not consent (10 patients; 3.5%), were
not at home or in hospital when visited (17; 6.0%), had
died (5; 1.8%), were initial defaulters (3; 1.1%), were
already in the continuation phase at the time point
when visited by the research team (25; 8.9%), or the
address in the registry was wrong or insufficient (18;
6.4%). The remaining 204 (72%) patients, 114 (56%)
men and 90 (44%) women, were found, provided
informed written consent and were interviewed. Their
mean age was 31 years and they reported a median
delay of 52 days until start of treatment; 122 (60%) were
sputum-smear positive patients and 153 (75%) were hos-
pitalised at some stage during the disease (table 1A).
Among women, most identifi e dt h e m s e l v e sa sh o u s e -
wives (58%) or farmers (12%). Among men, most
reported temporary labour migration to Russia (26%) or
unemployment (18%).
The mean total household costs of an episode of TB
were $1053 (± standard deviation $1601; median $378).
Patients reported household costs of $292 (± 620; 54)
before the start of DOTS treatment, costs of $338 (±
575; 139) during the intensive phase, and $422 (± 705;
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¾ of costs were encountered after the patients were
enrolled in the DOTS program. Direct costs amounted
to $152 (± 219; 47), $147 (± 213; 108), and $97 (± 111;
53) for the period up to start of DOTS treatment, inten-
sive phase, and continuation phase, respectively. Thus
direct costs amounted to $396 (± 357; 282) in total over
all periods and constituted 38% of total costs, the rest
being lost income. Table 2A shows that direct costs
most notably included costs for drugs (27% of total
direct costs), transportation (25%), and special foods
(29%). Drugs that were paid for mainly included vita-
mins and IV rehydration. The mean expenditure for the
anti-TB drugs (which are officially provided for free)
was very small: $0.35. Special foods included among
others different kinds of meats and animal fats that
were not consumed during times of good health or only
in smaller amounts. Indirect costs were mainly incurred
by patients themselves: 93 (79%) out of 117 patients
with complete information spent some time away from
usual income-generating activities. The median amount
of time away from work was 135 working days. For
those who worked seven days a week this would corre-
spond to 4.5 months, for those who worked five days a
week to 6.3 months. Among caretakers, 44 (36%) out of
122 cases with complete information spent a median of
24 working days away from work.
Household costs were not evenly spread over time.
Costs incurred during one month were $145 (± 296,
median 37) before start of DOTS treatment, $153
(± 256, 62) during the intensive phase, and $95 (± 159,
21) during the continuation phase (figure 2). Thus costs
incurred during one month were significantly higher
before start of treatment (paired t-test, p < 0.0005, n =
204) and during the intensive phase (p < 0.0005), both
compared to the continuation phase. The residual plot
suggested that a few observations might violate the
assumption of normality. We therefore conducted a sen-
sitivity analysis excluding these observations. Both dif-
ferences were still highly significant (and in the same
direction). The difference in monthly costs before start
of treatment compared to the intensive phase was also
significant (p = 0.001), but much smaller. While lost
income was relatively constant across the three periods,
direct costs per month were about 4.2 times higher
before start of DOTS treatment than during the conti-
nuation phase and about three times higher during the
intensive phase than during the continuation phase (p <
0.0005 for both comparisons). The difference between
the period before the start of treatment and the inten-
sive phase was not significant (p = 0.089). Thus costs
were most acute during early stages of treatment. This
was particularly the case for direct costs. However, pat-
terns varied considerably for individual line items (table
3A). Costs of drugs were highest during the intensive
phase and lowest before start of treatment. Costs of
diagnostic and laboratory tests, and similarly costs of
Table 1 Characteristics of study participants
Age Mean 31 years
Range 15-72 years
Form of TB Pulmonary 204 (100%)
Sputum smear positive 122 (60%)
History of TB disease New cases 204 (100%)
Delay until start of treatment Median patient delay 21.5 days
Median health system delay 16 days
Median total delay 52 days
Hospitalisation Hospitalised patients 153 (75%)
Median duration of hospitalisation 39 days
Direct observation of treatment Median number of visits for treatment observation 53 visits
Figure 1 Household costs of an episode of tuberculosis in
three separate periods of treatment. Direct costs (white), lost
income (black) and standard errors of total costs are shown. The
horizontal line denotes the annual per capita income [18].
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lowest during the continuation phase. Costs of transpor-
tation were by far highest before start of treatment.
Costs varied considerablyb yS E S .T h o s ei nt h el o w e r
three SES quintiles incurred less than half of the costs
of the highest SES quintile on average-$735, $773 and
$621 respectively versus $1735 (figure 3). This difference
was mainly due to higher income loss in the higher SES
quintiles, the mean income loss in the wealthiest quin-
tile being almost three times that of the poorest. Medi-
cal direct costs were similar across all SES quintiles;
non-medical costs of the wealthiest quintile were double
those of the poorest ($351 versus $168).
Discussion
The mean total household costs of a TB episode
amounted to $1053, corresponding to $4894 PPP. While
a considerable part of the scientific discussion on house-
hold costs has concentrated on the period before diag-
nosis [15-17], this study found that costs during
treatment account for three quarters of total costs-in a
setting with free TB drugs. Monthly costs were most
acute before treatment and during the intensive phase.
The total costs presented here do not yet take into
account that patients may incur costs after the end of
treatment; especially further loss of income for those
who have lost their jobs.
The study may seem only partly representative of Taji-
kistan, as two regions had to be excluded. One of the
r e g i o n s( B a d a k h s h a n )i sr emote and very sparsely
populated. The other one (Sughd) had only eight dis-
tricts with an established DOTS program at the time of
the study (versus 34 districts with DOTS in the whole
country) and was only accessible by air in winter. The
s t u d yi sr e p r e s e n t a t i v eo fa n area of Tajikistan, from
where 80% of all cases under DOTS came in the year
up to the study.
As other studies on household costs, this study also
relied on self-reported costs-it is thus not excluded that
patients forgot or overestimated some of the costs [7].
By using two interviews for separate periods of treat-
ment, this study limited recall time and recall bias.
Further we tried to limit the potential problem of over-
estimation by training the interviewers for this situation.
The mean total household costs found in this study were
even higher in terms of PPP than those found in other stu-
dies [12-14]. There may be several reasons for the high
costs found in this study and these are discussed in the fol-
lowing. One reason may be our methodology that reduced
recall bias. Further, there is a habit among TB specialists
in Tajikistan to hospitalise many TB patients and to pre-
scribe many drugs for perceived iatrogenic problems and
symptomatic treatment (own data, unpubl.). Hospitalisa-
tion itself does not usually have to be paid for, and this is
consistent with the fact that costs of medical fees, which
include hospitalisation fees, are relatively low (cf. table
2A). However, hospitalisation may be linked to other ser-
vices like the provision of additional medication. Addi-
tional drugs, including those for symptomatic treatment,
have to be paid for and it seems likely that these have led
to the very high costs of drugs during the intensive phase
(cf. table 3A). Only a small minority of patients reported
payments for anti-TB drugs. Costs of transportation were
very high before the start of treatment and this may point
Figure 2 Household costs incurred during one month during
three separate periods. Direct costs (white), lost income (black),
and standard errors of the total are shown. The horizontal line
denotes the monthly per capita income [18].
Figure 3 Household costs by socio-economic quintiles.D i r e c t
costs (white), lost income (black), and standard errors of the total
are shown. The horizontal line denotes the annual per capita
income [18].
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had developed active TB while being migrant workers in
Russia. These patients encountered high transportation
costs for their return to Tajikistan. An analysis of the diffi-
culties faced by migrant workers who develop active TB in
Russia is presented in a separate publication [35]. Informal
payments that occur in the health system are a further
potential reason for high costs. Disaggregating formal and
informal payments was not possible in our study, among
others because a health financing reform was ongoing dur-
ing the time of the study-including formalisation of some
informal payments. However, as reported above, the mean
payments for anti-TB drugs were very small.
Household costs were approximately three times
higher than the per capita GDP and thus must be con-
sidered catastrophic for affected households. As TB dis-
proportionately affects poorer segments of society this
burden may be even more catastrophic in the typical
TB-affected household than average GDP values indi-
cate. Direct costs were relatively similar for all SES quin-
tiles, while indirect costs, which depend on income,
were three times higher in the wealthiest compared to
the poorest quintile. This is suggestive of a regressive
cost burden at least for direct costs.
Monthly costs were especially high before enrolment in
DOTS treatment and during the intensive phase. Monthly
costs were significantly higher during these two periods
than during the continuation phase. This pattern was very
clear for direct and total costs, but less so for lost income,
which was more constant over the different phases of
treatment. Patients who stopped working often did so for
the duration of four months and more. This suggests that
they did not only stop working during the time of acute
illness, but for the whole treatment. Tajik doctors often
recommend them not to work during treatment and for
up to two years afterwards. Seasonality of income may
have led to underestimation of lost income especially
before the start of treatment, because patients were
enrolled into the study in the winter months, which is the
season when least work is available. Consequently, the
observed pattern of higher costs during early stages of
treatment may even be stronger in reality. The spread of
costs over time affects the ability of households to cope
with these costs [1], and our findings suggest that the pro-
blem of affordability of services is most acute in early
stages of treatment.
The high costs found in this study suggest that sheer
poverty and inability to cope with the economic burden
of treatment negatively affect treatment adherence and
treatment outcomes, as has been suspected in other
contexts [12,36]. Farmer et al [37] have shown that miti-
gation strategies including incentives for adherence can
improve treatment adherence among TB patients.
Donors and program managers need to implement
effective mitigation strategies to enable patients to
adhere to DOTS and to avoid severe impoverishment.
Table 2 Composition of household costs
Cost item Mean in US $ Standard Deviation Percentage of direct costs
Indirect costs 657 1391 N/A
Direct costs 396 357 100%
Medical costs 154 148 39%
Drug costs 107 105 27%
Costs of diagnostics and lab tests 18 19 4.5%
Costs of medical fees 29 64 7.3%
Non-medical costs 242 286 61%
Transportation 100 162 25%
Special foods 113 202 29%
Self-treatment & traditional medicine 16 41 4.0%
Other expenses 13 26 3.3%
Table 3 Variation of selected costs items over time [in US $]
Cost item Before start of treatment Intensive phase Continuation phase
Mean SD§ Mean SD§ Mean SD§
Drug costs 21.3 39.9 51.7 74.7 34.3 56.1
Costs of diagnostic and lab tests 7.8 16.2 7.4 8.7 2.5 3.9
Costs of medical fees 15.2 60.8 9.2 15.8 4.8 14.4
Transportation 71.2 139 8.2 12.9 20.4 26.4
Special foods 31.4 68.7 67.5 173 14.5 66.3
§SD = Standard deviation.
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must be timed early in treatment, when most of the
costs are incurred. A recent study from Russia has iden-
tified types of incentives that are preferred by TB
patients [38]. Additional strategies to reduce the eco-
nomic burden of TB disease on households might target
the high costs for drugs, which are related to the pre-
scription patterns including common use of sympto-
matic treatment. Studies from Russia have shown
features in the management of TB that are also found in
Tajikistan, including high hospitalisation rates and wide-
spread use of symptomatic treatment [39,40]. Further-
more similar factors influence hospitalisation in Russia
and Tajikistan [25,41]. These parallels suggest that some
of our results may also apply to Russia and other post-
Soviet countries.
Conclusions
During an episode of TB, patients and their households
face costs of approximately $4900 PPP. Comparison
with the per capita GDP of $1600 PPP shows that these
costs are catastrophic for the households concerned and
suggest a high risk for impoverishment. Costs are not
equally spread over time, but are highest in early stages
of treatment, exacerbating the problem of affordability.
Free TB drugs do not lead to free treatment and non-
TB drugs, transport, and loss of income are very impor-
tant cost drivers for patients. Mitigation strategies are
needed in order to control TB in Tajikistan and may
include social support to the patients as well as changes
in the management of TB cases. Mitigation strategies
need to be timed early in treatment when the cost bur-
den is highest. The provision of food supplements to TB
patients may contribute to somewhat alleviate the eco-
nomic burden. However, our results suggest that these
should be delivered soon after a TB diagnosis. Reducing
the use of non-TB drugs should be considered.
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